The FDA does not clear the way for phase 3... They recommend a path to follow if there's no safety concerns. It's the company's decision whether the data warrants money/time to continue. Great example was P... Leo felt it wasn't worth to continue, so an EOP meeting was not warranted.... FDA will only approve "final outcome" for public use